Tratamiento de la infección en la hepatitis C y la hemofilia

to treat hepatitis c new therapeutic protocols has been developed, based on pegilated interferon and ribavirine, and also natural virus eradication in a group of patients, however, cost studies of medical assistance reveal that it is significantly increased in hemophiliacs suffering hiv-infection and/or and hcv. impact of blood-transmitted diseases and emergent diseases on therapies with coagulation factors and on blood donation policies, raise the daily value attribute to recombinant products non dependent of blood sources, and to the processes of viral inactivation for substitution therapy. there are still therapeutic challenges for inhibitors haloantobodies formation versus some of the f-viii or f-ix concentrated products, be natural or recombinant, and the existence of non-equity and disparity in availability of the products, derived from differences as for licence status, as well as the high and still prohibitive prices to most patients in some world regions.